Ginkgo Bioworks Holdings Inc（DNA）の財務DNAGinkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings, Inc. (DNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cell Engineering, accounting for 75.7% of total sales, equivalent to $29.38M. Another important revenue stream is Biosecurity. Understanding this composition is critical for investors evaluating how DNA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ginkgo Bioworks Holdings, Inc. maintains a gross margin of 91.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -284.99%, while the net margin is -284.39%. These profitability ratios, combined with a Return on Equity (ROE) of -59.94%, provide a clear picture of how effectively DNA converts its operational activities into shareholder value.

In the context of the broader market, DNA competes directly with industry leaders such as SRTA and FLGT. With a market capitalization of $457.24M, it holds a significant position in the sector. When comparing efficiency, DNA's gross margin of 91.47% stands against SRTA's 11.84% and FLGT's 27.02%. Such benchmarking helps identify whether Ginkgo Bioworks Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Ginkgo Bioworks has reported a consistent decline in revenue, with Q2 2026 revenue at $20 million, down 48.7% year-over-year. The gross margin is strong at 91.47%, but the overall financial performance is marred by significant net losses, with a net income of -$57.32 million in Q2 2026.